AstraZeneca agreed Tuesday to pay $5.5 million in penalties and interest to settle claims that it violated the Foreign Corrupt Practices Act through improper payments to health care providers in China and Russia.
This premium content is reserved for Global Lawyer News subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now